About: Evaluation of Anti-Toxoplasma gondii Effect of Ursolic Acid as a Novel Toxoplasmosis Inhibitor

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Evaluation of Anti-Toxoplasma gondii Effect of Ursolic Acid as a Novel Toxoplasmosis Inhibitor Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Evaluation of Anti-Toxoplasma gondii Effect of Ursolic Acid as a Novel Toxoplasmosis Inhibitor
Creator	Choi, Won Lee, In
Source	Medline; PMC
abstract	This study was carried out to evaluate the anti-parasitic effect of ursolic acid against Toxoplasma gondii (T. gondii) that induces toxoplasmosis, particularly in humans. The anti-parasitic effects of ursolic acid against T. gondii-infected cells and T. gondii were evaluated through different specific assays, including immunofluorescence staining and animal testing. Ursolic acid effectively inhibited the proliferation of T. gondii when compared with sulfadiazine, and consistently induced anti-T. gondii activity/effect. In particular, the formation of parasitophorous vacuole membrane (PVM) in host cells was markedly decreased after treating ursolic acid, which was effectively suppressed. Moreover, the survival rate of T. gondii was strongly inhibited in T. gondii group treated with ursolic acid, and then 50% inhibitory concentration (IC(50)) against T. gondii was measured as 94.62 μg/mL. The T. gondii-infected mice treated with ursolic acid indicated the same survival rates and activity as the normal group. These results demonstrate that ursolic acid causes anti-T. gondii action and effect by strongly blocking the proliferation of T. gondii through the direct and the selective T. gondii-inhibitory ability as well as increases the survival of T. gondii-infected mice. This study shows that ursolic acid has the potential to be used as a promising anti-T. gondii candidate substance for developing effective anti-parasitic drugs.
has issue date	2018-05-09(xsd:dateTime)
bibo:doi	10.3390/ph11020043
bibo:pmid	29747388
has license	cc-by
sha1sum (hex)	745f78dadf6e5a2feb79900688cd5fb9ead4d72e
schema:url	https://doi.org/10.3390/ph11020043
resource representing a document's title	Evaluation of Anti-Toxoplasma gondii Effect of Ursolic Acid as a Novel Toxoplasmosis Inhibitor
has PubMed Central identifier	PMC6026977
has PubMed identifier	29747388
schema:publication	Pharmaceuticals (Basel)
resource representing a document's body	covid:745f78dadf6e5a2feb79900688cd5fb9ead4d72e#body_text
is schema:about of	named entity 'TOXOPLASMOSIS' named entity 'effective' named entity 'anti-parasitic' named entity 'animal testing' named entity 'anti-parasitic' named entity 'DEVELOPING' covid:arg/745f78dadf6e5a2feb79900688cd5fb9ead4d72e named entity 'EVALUATION' named entity 'TOXOPLASMA GONDII' named entity 'HUMANS' named entity 'DECREASED' named entity 'MICE' named entity 'EFFECT' named entity 'MEASURED' named entity 'GROUP' named entity 'USED' named entity 'FORMATION' named entity 'INCLUDING' named entity 'INHIBITOR' named entity 'INDICATED' named entity 'DRUGS' named entity 'INHIBITORY' named entity 'PARTICULAR' named entity 'POTENTIAL' named entity 'CAUSES' named entity 'CANDIDATE' named entity 'TREATING' named entity 'IMMUNOFLUORESCENCE STAINING' named entity 'SURVIVAL RATES' named entity 'MEMBRANE' named entity 'INFECTED' named entity 'THESE' named entity 'URSOLIC ACID' named entity 'NOVEL' named entity 'DIRECT' named entity 'TOXOPLASMOSIS' named entity 'SURVIVAL RATE' named entity 'SUBSTANCE' named entity 'STUDY' named entity 'ACTIVITY' named entity 'CARRIED' named entity 'BLOCKING' named entity 'ANTI-T' named entity 'NORMAL' named entity 'CONCENTRATION' named entity 'DIFFERENT' named entity 'ABILITY' named entity 'COMPARED' named entity 'INDUCED' named entity 'PARASITOPHOROUS VACUOLE' named entity 'SULFADIAZINE' named entity 'TREATED WITH' named entity 'MARKEDLY' named entity 'PARASITIC' named entity 'SELECTIVE' named entity 'INHIBITED' named entity 'ACTION AND EFFECT' named entity 'HOST CELLS' named entity 'CELLS' named entity 'URSOLIC ACID' named entity 'SURVIVAL' named entity 'INCREASES' named entity 'TOXOPLASMA GONDII' named entity 'SUPPRESSED' named entity 'EVALUATE' named entity 'RESULTS' named entity 'SPECIFIC' named entity 'ANIMAL TESTING' named entity 'PROLIFERATION' named entity '50%' named entity 'EFFECT' named entity 'EFFECTIVE' named entity 'group' named entity 'Toxoplasma' named entity 'proliferation' named entity 'effects' named entity 'potential' named entity 'acid' named entity 'activity' named entity 'survival rate'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software